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===========================================================

In the original publication of the article, the Figure 2b and the Tables 2 and 3 were published incorrectly.

The corrected Figure 2b and Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} are provided below. Table 2Incidence rate and univariate analysis by Cox proportional hazards analysis of stroke/systemic embolismNo. of event (%/year)HR95% CI*p* valueOverall176 (1.0)Sex Male115 (1.0)Reference*0.5283* Female61 (1.1)1.10.8, 1.5Age class 1 (years-old) \< 6523 (0.7)Reference*0.0176* ≥ 65153 (1.1)1.71.1, 2.6Age class 2 (years-old) \< 6523 (0.7)Reference*0.0022* 65--7460 (0.9)1.30.8, 2.2 ≥ 7593 (1.3)2.01.3, 3.2Body weight (kg) ≥ 6084 (0.8)Reference*0.0250* 50--5950 (1.1)1.30.9, 1.9 \< 5033 (1.4)1.71.1, 2.6Systolic blood pressure (mmHg) \< 160156 (1.0)Reference*0.0928* ≥ 16012 (1.6)1.60.9, 3.0CrCl (mL/min) ≥ 50112 (0.9)Reference*0.0026* 30--4949 (1.5)1.81.3, 2.5 \< 303 (1.0)1.20.4, 3.7Comorbidity^a^ Congestive heart failure  --129 (1.0)Reference*0.8550*  +47 (1.0)1.00.7, 1.4 Hypertension  --44 (0.9)Reference*0.2768*  +132 (1.1)1.20.9, 1.7 Angina pectoris  --157 (1.0)Reference*0.7193*  +19 (0.9)0.90.6, 1.5 Diabetes mellitus  --121 (0.9)Reference*0.0227*  +55 (1.3)1.41.1, 2.0 Aortic aneurysm  --174 (1.0)Reference*0.7916*  +2 (0.8)0.80.2, 3.3Deep vein thrombosis  --175 (1.0)Reference*0.9718*  +1 (1.0)1.00.2, 7.4 Pulmonary embolism  --175 (1.0)Reference*0.4012*  +1 (2.2)2.30.3, 16.2 Dyslipidemia  --105 (1.0)Reference*0.6278*  +71 (1.0)0.90.7, 1.3 Liver dysfunction  --167 (1.0)Reference*0.6999*  +9 (0.9)0.90.5, 1.7 Renal dysfunction  --176 (1.0)Reference*0.6995*  +0 (0.0)\< 0.001\< 0.001Medical history^a^ Stroke (ischemic/hemorrhagic)  --91 (0.7)Reference\< *0.0001*  +85 (2.3)3.62.7, 4.8 Transient ischemic attack  --169 (0.9)Reference*0.4721*  +7 (1.3)1.30.6, 2.8 Systemic embolism  --174 (1.0)Reference*0.6643*  +2 (1.4)1.40.3, 5.5 Vascular disease (MI/PAD)  --158 (1.0)Reference*0.0352*  +18 (1.6)1.71.0, 2.7 Malignant tumor  --159 (1.0)Reference*0.7657*  +17 (1.1)1.10.7, 1.8 Bleeding/disposition of bleeding  --169 (1.0)Reference*0.9900*  +7 (1.0)1.00.5, 2.1 Rivaroxaban dosage  15 mg/day87 (0.9)Reference*0.0658*  10 mg/day89 (1.2)1.31.0, 1.8 Amount of drinking (unit/week)  No105 (1.1)Reference*0.1202*  \< 847 (0.8)0.70.5, 1.0  ≥ 824 (1.0)0.90.6, 1.4 History of smoking  No99 (0.9)Reference*0.2940*  In the past54 (1.1)1.10.8, 1.6  Current23 (1.3)1.40.9, 2.2 Type of AF  PAF67 (0.9)Reference*0.0799*  Non-PAF^b^109 (1.1)1.31.0, 1.8 Using concomitant anti-platelets^a^  --138 (0.9)Reference*0.0046*  +38 (1.5)1.71.2, 2.4 Using concomitant NSAIDs^a^  --172 (1.0)Reference*0.9525*  +4 (1.0)1.00.4, 2.8 CHADS~2~ score  \< 376 (0.7)Reference\< *0.0001*  ≥ 3100 (1.7)2.72.0, 3.6 CHA~2~DS~2~-VASc score  \< 458 (0.6)Reference\< *0.0001*  ≥ 4118 (1.5)2.51.9, 3.5 HAS-BLED score  \< 260 (0.6)Reference\< *0.0001*  ≥ 2106 (1.7)2.82.0, 3.8*HR* hazard ratio, *CI* confidence interval, *CrCl* creatinine clearance, *MI* myocardial infraction, *PAD* peripheral arterial disease, *AF* atrial fibrillation, *PAF* paroxysmal atrial fibrillation, *NSAIDs* non-steroidal anti- inflammatory drugs^a^Reference; without factor^b^Persistent and permanent atrial fibrillationTable 3Incidence rate and univariate analysis by Cox proportional hazards analysis of ISTH major bleedingISTH major bleedingNo. of event (%/year)HR95% CI*p* valueOverall215 (1.2)Sex Male147 (1.2)Reference*0.8223* Female68 (1.2)1.00.7, 1.3Age class 1 (years-old) \< 6526 (0.7)Reference*0.0027* ≥ 65189 (1.4)1.91.2, 2.8Age class 2 (years-old) \< 6526 (0.7)Reference\< *0.0001* 65--7466 (1.0)1.30.8, 2.1 ≥ 75123 (1.7)2.41.6, 3.6Body weight (kg) ≥ 60125 (1.3)Reference*0.7249* 50--5952 (1.1)0.90.7, 1.3 \< 5031 (1.3)1.10.7, 1.6Systolic blood pressure (mmHg) \< 160199 (1.3)Reference*0.2772* ≥ 1606 (0.8)0.60.3, 1.4CrCl (mL/min) ≥ 50138 (1.1)Reference\< *0.0001* 30--4959 (1.8)1.81.3, 2.4 \< 309 (2.9)2.91.5, 5.6Comorbidity^a^ CHF  --149 (1.2)Reference*0.1140*  +66 (1.4)1.31.0, 1.7 Hypertension  --53 (1.1)Reference*0.1770*  +162 (1.3)1.20.9, 1.7 Angina pectoris  --181 (1.2)Reference*0.0543*  +34 (1.7)1.40.9, 2.1 Diabetes mellitus  --159 (1.2)Reference*0.4925*  +56 (1.3)1.10.8, 1.5 Aortic aneurysm  --210 (1.2)Reference*0.2144*  +5 (2.1)1.70.7, 4.2 DVT  --212 (1.2)Reference*0.0823*  +3 (3.1)2.60.9, 8.3 PE  --214 (1.2)Reference*0.5833*  +1 (2.2)1.70.2, 12.3 Dyslipidemia  --125 (1.2)Reference*0.9155*  +90 (1.2)1.00.8, 1.3 Liver dysfunction  --195 (1.2)Reference*0.0252*  +20 (2.0)1.71.1, 2.7 Renal dysfunction  --215 (1.2)Reference*0.6682*  +0 (0.0)\< 0.001\< 0.001, \> 999.9Medical history Stroke (ischemic/hemorrhagic)  --154 (1.1)Reference*0.0065*  +61 (1.7)1.51.1, 2.0 Transient ischemic attack  --208 (1.2)Reference*0.8415*  +7 (1.3)1.10.5, 2.3 Systemic embolism  --215 (1.2)Reference*0.1736*  +0 (0.0)\< 0.001\< 0.001, \> 999.9 Vascular disease (MI/PAD)  --196 (1.2)Reference*0.1345*  +19 (1.7)1.40.9, 2.3 Malignant tumor  --189 (1.2)Reference*0.1145*  +26 (1.7)1.40.9, 2.1 Bleeding/disposition of bleeding  --200 (1.2)Reference*0.0240*  +15 (2.1)1.81.1, 3.1 Rivaroxaban dosage  15 mg/day108 (1.1)Reference*0.0635*  10 mg/day107 (1.4)1.31.0, 1.7 Amount of drinking (unit/week)  No128 (1.4)Reference*0.0649*  \< 857 (1.0)0.70.5, 1.0  ≥ 830 (1.3)0.90.6, 1.4 History of smoking  No126 (1.2)Reference*0.4144*  In the past71 (1.4)1.20.9, 1.6  Current18 (1.0)0.90.5, 1.4 Type of AF  PAF89 (1.1)Reference*0.3453*  Non-PAF^b^126 (1.3)1.10.9, 1.5 Using concomitant anti-platelets^a^  --166 (1.1)Reference*0.0003*  +49 (2.0)1.81.3, 2.5 Using concomitant NSAIDs^a^  --211 (1.2)Reference*0.7265*  +4 (1.0)0.80.3, 2.3 CHADS~2~ score  \< 3121 (1.0)Reference*0.0009*  ≥ 394 (1.6)1.61.2, 2.1 CHA~2~DS~2~-VASc score  \< 492 (1.0)Reference*0.0001*  ≥ 4123 (1.6)1.71.3, 2.2 HAS-BLED score  \< 292 (0.9)Reference\< *0.0001*  ≥ 2111 (1.7)1.91.4, 2.5*HR* hazard ratio, *CI* confidence interval, *ISTH* International Society on Thrombosis and Haemostasis, *CrCl* creatinine clearance, *MI* myocardial infraction, *PAD* peripheral arterial disease, *AF* atrial fibrillation, *PAF* paroxysmal atrial fibrillation, *NSAIDs* non-steroidal anti-inflammatory drugs^a^Reference; without factor^b^Persistent and permanent atrial fibrillation
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